Targeting IGF1R may be a promising strategy for effectively controlling gefitinib-resistant CSCs in the hypoxic microenvironment and overcome hypoxia-induced resistance to EGFR-TKIs in NSCLC with an activating EGFR mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.